RJW & Partners strengthens senior level expertise with new Director

May 29, 2009 - PRLog -- Pricing and market access consultants to the pharmaceutical and medical device industries, RJW & Partners, are delighted to announce the appointment of Chloë Brown as Director and co-owner of the Company, strengthening the market access capability within the firm.

Chloë is a specialist in the area of value demonstration and expert in the delivery of data to support different messages that are market relevant whilst remaining true to the core development package of the product.   She joins from Mapi Values, where as Director of the French office and member of the Board, Chloë worked across the European offices on projects in the Health Technology Assessment area, delivering strategic and tactical approaches for European market access decision-makers.

Prior to joining Mapi Values, Chloë gained extensive consultancy experience as Principal at Cambridge Pharma Consultancy (now part of IMS Health), delivering global strategies to demonstrate the clinical and economic value of new and upcoming products in many therapeutic areas, including products that became leading brands in HIV, depression and gastrointestinal disease. She also gained valuable pharmaceutical industry experience with roles in global clinical research with Servier Laboratories and Cephalon.

Chloë holds a BA in Natural Sciences and a PhD in Pharmacology from Cambridge University, as well as a Diploma in Health Economics from the University of York.

Neil Johnson, one of the founding Directors of RJW & Partners said: “It’s a real coup to have Chloë in the team.  Having worked together over 10 years ago, developing the concept of a value story and value dossier, we coined the term ‘market access’ to reflect the broader nature of market-relevant value demonstration – these concepts and terms have now become industry standards. I look forward to working with her once again to develop the innovations of the future in terms of supporting the market access and health economics functions of our clients.”

Chloë explained: “Over the last few years, we have seen value demonstration becoming more entrenched in the clinical and regulatory areas.  The purpose of demonstrating value is to deliver data that tells a different story: one that is market relevant but still true to the core development package.  Getting data to support different messages in this area is what truly excites me and is where my core skills lie.  I am delighted to be working with Neil Johnson and Ad Rietveld again as we share a common philosophy in this area, but approach it from our different experience bases to ensure our client deliverable is richer, more complete and utterly market relevant.”

RJW & Partners offer a complete suite of services spanning every stage of the product lifecycle including: pricing and market access strategy development, support planning and audit, global and affiliate strategy implementation, the evaluation of new in or out-licensing opportunities and organisational development and improvement.  At the core of each assignment is the wish to make a meaningful and commercially tangible contribution to the development of the client’s business, at whatever stage.

# # #

About RJW & Partners: RJW & Partners was founded in 2008 and is a consultancy with unique capabilities in pricing and market access, focused solely on the pharmaceutical and healthcare sectors. All senior staff have worked at the highest levels in pricing and market access in either government or industry and throughout their consulting careers have personally advised on the pricing and market access strategies for most of today’s leading pharmaceutical brands. The company operates throughout Europe, the US, Canada, Asia-Pacific and Latin America. www.rjwpartners.com